NEWS 8K
On October 24, 2024, Revance Therapeutics, Inc. (the “Company”) and Teoxane SA (“Teoxane”), entered into the Sixth Amendment to the Exclusive Distribution Agreement (the “Sixth Amendment”). As previously disclosed on a Current Report on Form 8-K filed on January 10, 2020, the Company entered into the Exclusive Distribution Agreement with Teoxane on January 10, 2020 (the “Distribution Agreement”), pursuant to which Teoxane granted the Company with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid dermal fillers and future Hyaluronic Acid filler advancements by Teoxane in the United States, its territories and possessions (collectively, the “RHA® Collection”), which is manufactured in Switzerland by Teoxane.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2646Followers
107Following
28KVisitors
Follow